YEEDO News
-
LIVE BROADCAST | Drug-drug Interaction Evaluation Strategies: From In Vitro to Clinical Studies
Yeedozencom will hold an online broadcast titled “Yeedo Share” on September 12, at 19:00. Dr. Yu Feifei, Deputy Director of the Medical Department at Yeedozencom, will present on the topic of “Drug-drug Interaction Evaluation Strategies: From In Vitro to Clinical Studies”.2024-09-12 -
GOOD NEWS | Congratulations to Homesun Pharmaceutical on the Marketing Approval of Levofloxacin Tablets, Amiodarone Hydrochloride Injection, and Acetylcysteine Solution for Inhalation
Recently, Suzhou Homesun Pharmaceutical Co., Ltd. (hereinafter referred to as “Homesun Pharmaceutical”), received approval letters from the National Medical Products Administration (NMPA) for their products Levofloxacin Tablets (0.5 g), Amiodarone Hydrochloride Injection (3 mL:150 mg), and Acetylcysteine Solution for Inhalation (3 mL:0.3 g).2024-09-12 -
GOOD NEWS | Congratulations to GenFleet Therapeutics on the marketing approval of their innovative drug, Fulzerasib
On August 21, 2024, Dupert® (Fulzerasib tablets) developed by GenFleet Therapeutics was approved by the National Medical Products Administration (NMPA) for marketing as a treatment of advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) in patients who have received at least one prior line of systemic therapy, marking it as the first approved KRAS G12C inhibitor in China.2024-09-12 -
GOOD NEWS | Phase 1 clinical trial of the innovative drug OAB-14 of Xinhua Pharmaceutical for the treatment of Alzheimer’s disease successfully completes
On August 22, Xinhua Pharmaceutical convened a summary meeting for the phase 1 clinical study of its innovative drug OAB-14 indicated to treat Alzheimer’s disease (AD) and organized an expert review of the phase 2 clinical study protocol of this product in Beijing.2024-09-09 -
GOOD NEWS | Yeedozencom assisted Yidu Biotechnology in successfully convening the project kickoff meeting for the phase 4 clinical trial of the “Rabies Vaccine (Vero Cell)”
On July 16, 2024, the kickoff meeting for the phase 4 clinical trial of the freeze-dried human rabies vaccine, initiated by Shandong Yidu Biotechnology Co., Ltd. (hereinafter referred to as “Shandong Yidu”), was successfully convened at the Xuanhan County Center for Disease Control and Prevention2024-09-09 -
GOOD NEWS丨Yeedozencom assisted Laiduo in the approval of ursodeoxycholic acid capsule for marketing
Congratulations to Shaoxing Laiduo Technology Co., Ltd. (hereinafter referred to as " Laiduo ") on the approval of Ursodeoxycholic Acid Capsule and thanks to Laido for their trust in Yeedozencom!2024-06-17
